Absent CD56 expression in papillary thyroid carcinoma: A finding of potential diagnostic value in problematic cases of thyroid pathology

Journal of Research in Medical Sciences

Volumn 18, Issue 12, 2013, Pages 1046-1050

  Mokhtari, Mozhgan ^a   Eftekhari, Mehdi ^a   Tahririan, Reza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CD56; Papillary thyroid carcinoma; Thyroid neoplasms; Thyroid nodule

Indexed keywords

EID: 84893152755     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Gharib H, Papini E. Thyroid nodules: Clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am 2007;36:707-35.
2. Topliss D. Thyroid incidentaloma: The ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 2004;60:18-20.
3. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
4. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 2004;89:3214-23.
5. Chan J. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002;117:16-8.
6. El Demellawy D, Nasr A, Alowami S. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 2008;3:5.
7. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005;18:48-57.
8. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-42.
9. Baloch ZW, LiVolsi VA. Fine-needle aspiration of thyroid nodules: Past, present, and future. Endocr Pract 2004;10:234-41.
10. Albores-Saavedra J, Wu J. The many faces and mimics of papillary thyroid carcinoma. Endocr Pathol 2006;17:1-18.
11. Schmid KW, Farid NR. How to define follicular thyroid carcinoma? Virchows Arch 2006;448:385-93.
12. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-40.
13. Saxen E, Franssila K, Bjarnason O, Normann T, Ringertz N. Observer variation in histologic classification of thyroid cancer. Acta Pathol Microbiol Scand A 1978;86A:483-6.
14. Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D. Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 2008;19:92-6.
15. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005;47:391-401.
16. Zeromski J, Bagnasco M, Paolieri F, Dworacki G. Expression of CD56 (NKH-1) differentiation antigen in human thyroid epithelium. Clin Exp Immunol 1992;89:474-8.
17. Zeromski J, Dworacki G, Jenek J, Niemir Z, Jezewska E, Jenek R, et al. Protein and mRNA expression of CD56/N-CAM on follicular epithelial cells of the human thyroid. Int J Immunopathol Pharmacol 1999;12:23-30.
18. Scarpino S, Di Napoli A, Melotti F, Talerico C, Cancrini A, Ruco L. Papillary carcinoma of the thyroid: Low expression of NCAM (CD56) is associated with downregulation of VEGF-D production by tumour cells. J Pathol 2007;212:411-9.
19. El Demellawy D, Nasr AL, Babay S, Alowami S. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. Pathol Res Pract 2009;205:303-9.
20. LiVolsi VA, Baloch ZW. Follicular neoplasms of the thyroid: View, biases, and experiences. Adv Anat Pathol 2004;11:279-87.
21. Hoos A, Stojadinovic A, Singh B, Dudas ME, Leung DH, Shaha AR, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol 2002;160:175-83.
22. Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989;169:2233-8.
23. Zeromski J, Lawniczak M, Galbas K, Jenek R, Golusinski P. Expression of CD56/N-CAM antigen and some other adhesion molecules in various human endocrine glands. Folia Histochem Cytobiol 1998;36:119-25.
24. Zeromski J, Biczysko M, Stajgis P, Lawniczak M, Biczysko W. CD56(NCAM) antigen in glandular epithelium of human thyroid: Light microscopic and ultrastructural study. Folia Histochem Cytobiol 1999;37:11-7.
25. Park WY, Jeong SM, Lee JH, Kang HJ, Sin DH, Choi KU, et al. Diagnostic value of decreased expression of CD56 protein in papillary carcinoma of the thyroid gland. Basic Appl Pathol 2009;2:63-8.
26. Etem H, Özekinci S, Mizrak B, Şentürk S. The Role of CD56, HBME-1, and p63 in follicular neoplasms of the thyroid. Turk Patoloji Derg 2010;26:238-42.
27. Ozolins A, Narbuts Z, Strumfa I, Volanska G, Gardovskis J. Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg 2010;395:885-91.
28. Abd El Atti RM, Shash LS. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. J Egypt Natl Canc Inst 2012;24:175-84.
29. Lee S, Hong S, Koo JS. Immunohistochemical subclassification of thyroid tumors with a prominent hyalinizing trabecular pattern. APMIS 2011;119:529-36.
30. Huerta S, Srivatsan ES, Venkatesan N, Peters J, Moatamed F, Renner S, et al. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery 2001;130:834-43.
31. Fogar P, Basso D, Pasquali C, De Paoli M, Sperti C, Roveroni G, et al. Neural cell adhesion molecule (N-CAM) in gastrointestinal neoplasias. Anticancer Res 1997;17:1227-30.
32. Rutishauser U, Acheson A, Hall AK, Mann DM, Sunshine J. The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science 1988;240:53-7.
33. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGFreceptor signalling. Nat Cell Biol 2001;3:650-7.
34. Kim JH, Kim YH, Han JH, Lee KB, Sheen SS, Lee J. Silencing of homeobox B9 is associated with down-regulation of CD56 and extrathyroidal extension of tumor in papillary thyroid carcinoma. Hum Pathol 2012;43:1221-8.
35. Fellmer PT, Sato K, Tanaka R, Okamoto T, Kato Y, Kobayashi M, et al. Vascular endothelial growth factor C gene expression in papillary and follicular thyroidcarcinomas. Surgery 1999;126:1056-61.